# Nutriband Inc. (NASDAQ: NTRB) Pioneers Innovative Approach to Opioid Crisis with Game-Changing Transdermal Patch

* The opioid epidemic has prompted a re-evaluation of pain-management strategies, highlighting the importance of balancing effective treatment with abuse prevention
* Nutriband’s AVERSA(TM) Fentanyl represents a significant advancement in this domain
* The company’s strategic development of AVERSA Fentanyl follows a structured pharmaceutical lifecycle

 As the opioid crisis continues to challenge public health systems, the need for innovative solutions has become increasingly apparent. Rather than relying solely on restrictive measures, companies such as Nutriband (NASDAQ: NTRB) are exploring technological advancements to mitigate abuse while ensuring patient access to necessary medications. Nutriband’s development of AVERSA(TM) Fentanyl, an abuse-deterrent transdermal patch, exemplifies this forward-thinking approach (https://ibn.fm/jhHMY).

 The opioid epidemic has prompted a reevaluation of pain-management strategies, highlighting the importance of balancing effective treatment with abuse prevention. Traditional methods often involve limiting prescriptions, which can inadvertently hinder patients with…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/nutriband-inc-nasdaq-ntrb-pioneers-innovative-approach-to-opioid-crisis-with-game-changing-transdermal-patch/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/nutriband-inc-pioneers-innovative-approach-to-opioid-crisis-with-game-changing-transdermal-patch/d801b29f41683271d44e77207c62a8f4) 

 



[Reddit Post](https://www.reddit.com/r/HealthCareNewsInfo/comments/1klt6xs/nutriband_inc_pioneers_innovative_approach_to/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/255/13/yarn6tao.webp)